Today: 30 June 2026
Browse Category

NYSE:GPUS 28 October 2025

Hyperscale Data (GPUS) Skyrockets on Bitcoin Bonanza and AI Cloud Pivot – What’s Driving the Rally?

Hyperscale Data (GPUS) Skyrockets on Bitcoin Bonanza and AI Cloud Pivot – What’s Driving the Rally?

Hyperscale Data’s stock is on a tear this week. Shares of the Las Vegas-based company surged over 24% in pre-market trading Tuesday and extended gains into the sessionseekingalpha.com. By midday October 28, GPUS was up around 28% at roughly $0.64benzinga.com, building on a spectacular after-hours jump the night before. On Monday, the micro-cap stock rocketed 24.5% during regular trading to $0.4979, then leapt another ~33% after hours to about $0.66ts2.tech. The two-day jolt has nearly doubled Hyperscale’s market value, putting it on the radar of many retail traders. Online forums buzzed about the tiny $0.50-range stock as a speculative “AI + Bitcoin” play, especially after the company’s recent name change to “Hyperscale” and news of a high-profile Nvidia partnershipts2.tech. Despite the explosive rally, context is important. Even at around 65 cents, GPUS remains deep in penny-stock territory and, in fact, still sits roughly 90% below its levels at the start of 2025ts2.tech. Just a year ago the stock traded in the $5–$7 range, before a prolonged slide driven by repeated share dilution and financial strugglests2.tech. The company dramatically expanded its share count this fall – issuing millions of new common shares through preferred stock conversions and notes – which helped

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Go toTop